PHASE-II TRIAL OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN ADVANCED RECURRENT ENDOMETRIAL CARCINOMA

A phase II combination chemotherapy protocol combining methotrexate, v inblastine, doxorubicin, and cisplatin was designed to evaluate tumor response and survival in patients with advanced/recurrent endometrial carcinoma. Thirty patients with advanced/recurrent endometrial carcino ma were assigned to chemotherapy treatment at 4-week intervals with me thotrexate 30 mg/m(2) iv Days 1, 15, and 22; vinblastine 3 mg/m(2) iv Days 2, 15, and 22; doxorubicin 30 mg/m(2) iv Day 2; and cisplatin 70 mg/m(2) iv Day 2. After a median of four cycles (maximum number two cy cles beyond complete regression; minimum six cycles for stable partial regression), we observed objective regressions in 20 patients (67%) ( 95% Cl, 50, 84) with complete regression in 8 patients (27%) and parti al regression in 12 patients (40%). Median overall survival was 9.9 mo nths (range, 03-34.2), and median survival of responders was 11.0 mont hs (range, 2.6-34.2) from initial date of response. Toxicity was subst antial with two treatment-related deaths and consisted predominantly o f neutropenia (grade 3 or greater in 93% of the patients), alopecia, n ausea, emesis, stomatitis, and azotemia In conclusion, MVAC is a highl y active outpatient chemotherapy regimen in patients with advanced/rec urrent endometrial carcinoma, achieving a high complete and partial re sponse rate. Toxicity is substantial in this elderly patient populatio n. (C) 1995 Academic Press, Inc.